Partial agonist

Tallac Presents First Clinical Data for TAC-001 at SITC 2023

Retrieved on: 
Venerdì, Novembre 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, PD, CD22, Mount Tallac, TLR9, Poster, Multimedia, SITC, Immunotherapy, Immunity, MOA, RECIST, Melanoma, Immunology, Cancer, Therapy, Partial agonist, TRAAC, Vaccine, Pharmaceutical industry, Pharmacokinetics

“These TAC-001 clinical data provide evidence that systemic administration of a TLR9 immune agonist targeting and activating B cells is generally well tolerated and induces immune activation consistent with preclinical studies.

Key Points: 
  • “These TAC-001 clinical data provide evidence that systemic administration of a TLR9 immune agonist targeting and activating B cells is generally well tolerated and induces immune activation consistent with preclinical studies.
  • TAC-003 has completed pre-clinical testing, including exploratory toxicological studies in cynomolgus monkeys, and has been selected as the Company’s third clinical candidate.
  • “We are excited to see these initial clinical data with TAC-001, the first program from Tallac’s TRAAC platform,” said Dr. Hong I. Wan, president, CEO and co-founder of Tallac Therapeutics.
  • Tallac Therapeutic’s TRAAC platform is designed to deliver a potent and differentiated TLR9 agonist (T-CpG) for targeted immune activation via systemic administration.